menu

Emerging Antipsychotic Strategies in Bipolar I Disorder and Schizophrenia: Translating Findings from Clinical Trials to Individu

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Emerging Antipsychotic Strategies in Bipolar I Disorder and Schizophrenia: Translating Findings from Clinical Trials to Individual Patients

close
4 chapters
Play All
0.50 credits
30 minutes
Chapter 1
ReachMD Healthcare Image
Restart
Resume
Read full article
Choose a format
Get your free creditsSkip straight to the post-test if you have already participated in this activity
Media formats available:
0.50 credits
A pre-test is required to view this content.
A pre-survey is required to view this content.
Details
Presenters
Comments
  • Overview

    Dr. Leslie Citrome and Dr. Christoph Correll discuss the clinical trial data of current and emerging antipsychotic therapy for bipolar I disorder and schizophrenia. They provide insight on how to apply this clinical data into everyday practice and explore the best strategies to improve patient-centric issues for people coping with these illnesses.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Commercial Support, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. GLC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Leslie Citrome, MD, MPH 
    Clinical Professor of Psychiatry and Behavioral Sciences
    New York Medical College
    Valhalla, NY

    Consulting Fees: Acadia, Alkermes, Allergan, Avanir, BioXcel, Eisai, Impel, Indivior, Intra-Cellular Therapies, Janssen, Lundbeck, Luye, Merck, Neurocrine, Noven, Osmotica, Otsuka, Pfizer, Sage, Shire, Sunovion, Takeda, Teva, Vanda
    Speakers Bureau: Acadia, Alkermes, Allergan, Janssen, Lundbeck, Merck, Neurocrine, Otsuka, Pfizer, Sage, Shire, Sunovion, Takeda, Teva
    Stock Options: BMS, Eli Lilly, J&J, Merck, Pfizer
    Royalties: Wiley (Editor-in-Chief, International Journal of Clinical Practice, through end 2019), UpToDate (reviewer), Springer Healthcare (book), Elsevier (Topic Editor, Psychiatry, Clinical Therapeutics)

    Christoph U. Correll, MD 
    Professor of Psychiatry
    Zucker School of Medicine at Hofstra/Northwell
    Hempstead, NY 

    Consulting Fees: Acadia, Alkermes, Allergan, Angelini, Axsom, Gedeon Richter, Gerson Lehrman Group, Indivior, Intra-Cellular Therapies, Janssen/J&J, Karuna, LB Pharma, Lundbeck, MedAvante-ProPhase, MedInCell, Merck, Mitsubishi Tanabe Pharma, Mylan, Neurocrine, Noven, Otsuka, Pfizer, Recordati, Rovi, Servier, Sumitomo Dainippon, Sunovion, Supernus, Takeda, Teva
    Contracted Research: Janssen, Takeda
    Stock Options: LB Pharma

    Reviewers/Content Planners/Authors:

    • Stephen Chavez has nothing to disclose.
    • Libby Lurwick has nothing to disclose..
    • Brian P. McDonough MD, FAAFP has nothing to disclose.
    • Tricia O’Leary has nothing to disclose.
    • Colleen Resnick has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Identify key clinical trial data on emerging approaches that may improve adherence among patients who require treatment with oral antipsychotic therapy
    • Discuss strategies to support patient-provider partnerships that improve outcomes for patients with bipolar I disorder or schizophrenia who require antipsychotic therapy
    • Discuss data assessing the comparative efficacy of oral antipsychotic agents
  • Target Audience

    This activity is designed to meet the educational needs of psychiatrists, psychiatry nurse practitioners, and psychiatry physician assistants.

  • Accreditation and Credit Designation Statements

    Global Learning Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Global Learning Collaborative designates this enduring material for a maximum of .25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider

    ReachMD Healthcare Image

    Prova Education, designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties. 

    Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the very best education in the most impactful manner and to verify its results with progressive outcomes research. 

  • Commercial Support

    This activity is supported by an independent educational grant from Alkermes, Inc.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited

    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Recommended
Details
Presenters
Comments
  • Overview

    Dr. Leslie Citrome and Dr. Christoph Correll discuss the clinical trial data of current and emerging antipsychotic therapy for bipolar I disorder and schizophrenia. They provide insight on how to apply this clinical data into everyday practice and explore the best strategies to improve patient-centric issues for people coping with these illnesses.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Commercial Support, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. GLC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Leslie Citrome, MD, MPH 
    Clinical Professor of Psychiatry and Behavioral Sciences
    New York Medical College
    Valhalla, NY

    Consulting Fees: Acadia, Alkermes, Allergan, Avanir, BioXcel, Eisai, Impel, Indivior, Intra-Cellular Therapies, Janssen, Lundbeck, Luye, Merck, Neurocrine, Noven, Osmotica, Otsuka, Pfizer, Sage, Shire, Sunovion, Takeda, Teva, Vanda
    Speakers Bureau: Acadia, Alkermes, Allergan, Janssen, Lundbeck, Merck, Neurocrine, Otsuka, Pfizer, Sage, Shire, Sunovion, Takeda, Teva
    Stock Options: BMS, Eli Lilly, J&J, Merck, Pfizer
    Royalties: Wiley (Editor-in-Chief, International Journal of Clinical Practice, through end 2019), UpToDate (reviewer), Springer Healthcare (book), Elsevier (Topic Editor, Psychiatry, Clinical Therapeutics)

    Christoph U. Correll, MD 
    Professor of Psychiatry
    Zucker School of Medicine at Hofstra/Northwell
    Hempstead, NY 

    Consulting Fees: Acadia, Alkermes, Allergan, Angelini, Axsom, Gedeon Richter, Gerson Lehrman Group, Indivior, Intra-Cellular Therapies, Janssen/J&J, Karuna, LB Pharma, Lundbeck, MedAvante-ProPhase, MedInCell, Merck, Mitsubishi Tanabe Pharma, Mylan, Neurocrine, Noven, Otsuka, Pfizer, Recordati, Rovi, Servier, Sumitomo Dainippon, Sunovion, Supernus, Takeda, Teva
    Contracted Research: Janssen, Takeda
    Stock Options: LB Pharma

    Reviewers/Content Planners/Authors:

    • Stephen Chavez has nothing to disclose.
    • Libby Lurwick has nothing to disclose..
    • Brian P. McDonough MD, FAAFP has nothing to disclose.
    • Tricia O’Leary has nothing to disclose.
    • Colleen Resnick has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Identify key clinical trial data on emerging approaches that may improve adherence among patients who require treatment with oral antipsychotic therapy
    • Discuss strategies to support patient-provider partnerships that improve outcomes for patients with bipolar I disorder or schizophrenia who require antipsychotic therapy
    • Discuss data assessing the comparative efficacy of oral antipsychotic agents
  • Target Audience

    This activity is designed to meet the educational needs of psychiatrists, psychiatry nurse practitioners, and psychiatry physician assistants.

  • Accreditation and Credit Designation Statements

    Global Learning Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Global Learning Collaborative designates this enduring material for a maximum of .25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider

    ReachMD Healthcare Image

    Prova Education, designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties. 

    Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the very best education in the most impactful manner and to verify its results with progressive outcomes research. 

  • Commercial Support

    This activity is supported by an independent educational grant from Alkermes, Inc.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited

    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Schedule26 Oct 2021
Webpack App